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Abstract 
Polymeric microbubbles (MBs) are gas filled particles composed of a thin stabilized polymer 
shell that have been recently developed as valid contrast agents for the combined use of 
ultrasonography (US), magnetic resonance imaging (MRI) and single photon emission 
computer tomography (SPECT) imaging. Due to their buoyancy, the commonly available 
approaches to study their behaviour in complex media are not easily applicable and their use 
in modern medicine requires to be fully elucidated. Here we have used for the first time flow 
cytometry as a new high throughput approach that allows to characterize the MB dispersions, 
prior and after exposure in different biological media and we have additionally developed a 
method that allows to characterise the strongly bound proteins adsorbed on the MBs, to fully 
predict their biological behaviour in biological milieu.  
 
Keywords: microbubbles, protein corona, flow cytometry, opsonin proteins, disopsonin 
proteins, bionano interactions  
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1. Introduction 
Recent advances in nano and micro-material research have made possible many applications 
in modern nanomedicine where various particle types have been developed with the potential 
use as drug carriers for therapeutic purposes (Ferrari, 2005, Peyratout and Dahne, 2004) and 
as diagnostic imaging tools (Colvin, 2003, Gao et al. , 2008). It is now well-established that 
nanomaterials, as also observed for larger biomaterials upon exposure to biological fluids, 
such as human plasma, are immediately coated by biomolecules that form a biomolecular 
layer which represent the key to their biological impacts, hereafter called the “protein corona” 
(Aggarwal et al. , 2009, Maiolo et al. , 2015, Milani et al. , 2012, Monopoli et al. , 2011, Nel 
et al. , 2009, Rocker et al. , 2009, Tenzer et al. , 2013, Wan et al. , 2015, Yan et al. , 2013). 
This biomolecular corona is typically composed of an outer weakly interacting layer of 
proteins (the dynamic corona) (Milani, Baldelli Bombelli, 2012), which is rapidly exchanging 
with free proteins in the biological milieu, and an inner hard corona of proteins strongly 
bound to the nanomaterial surface that are slowly exchanging and reside on the surface for 
longer residence times. Previous studies on several different nanomaterials have shown that 
from the roughly 3700 proteins present in human plasma, whose abundance varies over 
several orders of magnitude, only a few tens of proteins with high affinity (for a particular 
material) are associated with any specific nanomaterial surface with sufficient residence time 
to provide a biological identity for that nanomaterial (Bigdeli et al. , 2016, Casals et al. , 
2010, Cedervall et al. , 2007, Hadjidemetriou et al. , 2015b, Monopoli et al. , 2012, Tenzer, 
Docter, 2013, Walkey and Chan, 2012, Wan, Kelly, 2015). Thus, the biological machinery is 
not likely to “see” the pristine surface of such materials (Ge et al. , 2011, Lesniak et al. , 
2012, Walczyk et al. , 2010).  
The properties of nanomaterials such as their shape, charge, surface chemistry, functional 
groups and material impact the protein corona composition which may lead to different 
biological consequences (Sund et al. , 2011, Walkey and Chan, 2012). For example, binding 
of opsonin proteins (e.g., fibrinogen, complement proteins and immunoglobulins) to particles 
can lead to recognition by macrophages, (Konduru et al. , 2009) promoting cellular uptake 
(Lunov et al. , 2011) and inflammation,(Boraschi et al. , 2012, Ishida et al. , 2001) while, 
binding of disosponin proteins (e.g., serum albumin, transferrin and lipoproteins) is likely to 
favour prolonged circulation time in the blood stream and may confer improved 
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biocompatibility of nanomaterials (Camner et al. , 2002, Hadjidemetriou et al. , 2015a, 
Mahmoudi et al. , 2011, Palchetti et al. , 2016).  
Recent studies have shown that other biomolecules form the corona and their component has 
a strong impact on the biological response. For example Wan and co-authors have recently 
highlighted the importance of the carbohydrates at the bionano interface (Wan, Kelly, 2015), 
and increasing studies, using lung lining fluids, have shown how the lipids and the surfactant 
proteins can modulate the protein corona composition. (Konduru, Tyurina, 2009, Kumar et al. 
, 2016, Raesch et al. , 2015).  
Due to the buoyancy of the MBs, the use of standard physico-chemical characterisation 
methods and approaches for the MB corona complexes isolation are not easily applicable. We 
describe here an alternative method which allows the characterization of MB protein coronas 
in a high throughput manner by means of flow cytometry, a tool used until now mainly in cell 
biology. By means of this technique we illustrate that flow cytometry is capable of providing 
information about the MB concentration, on the dispersion properties in complex media and 
it is also a useful method to isolate MB strongly bound protein corona complexes. 
 
 
2. Materials and methods 
2.1 Microbubbles 
The PVA MBs were made of a shell of crosslinked poly(vinyl alcohol), while the Type B 
MBs were synthesized by embedding iron oxide magnetic nanoparticles into the poly(vinyl 
alcohol) shell. Various types of layer-by-layer MBs (LBL) were also provided for our studies. 
These LBL MBs were all multilayer MBs which were made using the same aminoguanidine 
shell (e.g., LBL02, shell only), but with different specific materials introduced into the 
aminoguanidine shell (e.g., LBL 03-11). All the above MBs were in the size range 2~4.5 µm 
and collectively possessed a similar surface curvature. Various coatings on the MB shells 
were designed to improve their surface functionality, and improve their use as contrast 
agents.  Table 1 provides a summary descriptions of the MBs used in the study in terms of 
their shell composition and outer surface layer charge. 
2.2 Physico-chemical characterization of MBs by flow cytometry 
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The stock solution of MBs was mixed for 5-10 seconds using a vortex mixer until the MBs 
were homogeneously dispersed (as determined by visual inspection). 106 MBs were diluted in 
1ml in relevant media (such as PBS or the biological fluid of choice, such as 6% human 
plasma, 10% bovine serum, full human plasma and full human blood) and this dose 
corresponds to a typical dose used for in vivo imaging (Brismar et al. , 2012). Following 
incubation the sample was analysed by flow cytometer using an Accuri C6 system (BD 
Biosciences). MBs sub-populations were isolated in a FACSAria™ III cell sorter (also from 
BD). Non-fluorescent MBs were detected by their forward and side scattering. The fluid flow 
in the flow cytometer was fixed at a speed of 14 µl per minute in all cases. 
 
2.3 Biological fluid 
Human plasma was obtained from the Irish Blood Transfusion Service (IBTS), St. James 
Hospital following their internal procedure. Human blood was obtained from three male and 
three female healthy donors. After collection the plasma was pooled and stored at -80 °C in 
2ml aliquots. Human plasma was tested for total protein content using the bicinchoninic acid 
assay (BCA assay, Pierce) and for protein dispersion by size exclusion chromatography (data 
not shown). Foetal bovine serum (FBS) serum was obtained from Gibco (Biosciences, 
Ireland). 
On the day of each experiment, biological fluid was allowed to thaw at room temperature 
until the solution looked clear, then centrifuged for 3minutes at 16,000 rcf. The plasma was 
diluted to required concentration in 1mM EDTA phosphate buffered saline (PBS). 
2.4 Protein corona isolation from human plasma  
For each MB type, MBs were incubated with the biological fluid of choice (6% plasma, 10% 
serum or ~100% undiluted plasma) for 1 hour at 37ºC under agitation. They were 
subsequently allowed to float to the surface of the solution for 120 minutes without agitation 
and the medium below the MBs was carefully removed with a needle-assembled syringe. 
MB-protein corona complexes were then washed 5 times with 1 ml of PBS (allowing the 
MBs to float to the surface each time for 30 minutes) to remove loosely bound proteins (the 
so-called soft corona) in order to isolate only the strongly bound proteins (the so-called hard 
corona). Prior to running on an SDS-PAGE gel, MB-protein corona complexes were counted 
using a counting chamber (haemocytometer) in phase contrast microscopy and the number of 
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MBs were calculated such that identical numbers of each MB type / replicate were applied 
for the gel loading.  
 
2.5 Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) 
To characterize the protein corona formed on the MBs, the isolated MB-protein samples were 
run in SDS-PAGE gel electrophoresis. Prior to the electrophoresis, the proteins bound to the 
MBs were denatured and linearized in the presence of surfactant (sodium dodecyl sulphate 
SDS) and reducing agents (DTT) by boiling the solutions at 95oC for 5 min. The sample then 
was loaded into a 10 %polyacrylamide gel and the proteins were separated under electric 
field in the gel matrix according to the protein molecular weight. To detect the protein bands, 
the gel was stained using silver staining for protein band detection and using coomassie blue 
staining for mass spectrometry analysis. The separated proteins were then compared with the 
standard protein ladder to analyze the protein distribution.   
2.6 Mass spectrometry 
To determine the protein corona composition, the gel lanes containing the protein corona 
associated with specific MBs were cut out from the gel following SDS-PAGE gel 
electrophoresis as described above and following by gel based mass spectrometry analysis. 
The digested protein bands were then re-suspended in 0.1%formic acid. Electrospray liquid 
chromatography mass spectrometry (LC MS/MS) equipped with an HPLC (Surveyor, 
ThermoFinnigan, CA) interfaced with an LTQ Orbitrap (ThermoFinnigan, CA) was used to 
analyze the peptide mixtures following typsin digestion. Spectra were searched with 
BioworksBrowser 3.3.1 SP1 (ThermoFisher Scientific) using Sequest Uniprot/Swiss-Prot 
database (www.expasy.org).  When the same protein identity was detected in multiple bands 
from the same samples, their SpCs were summed to get the total protein amount. The spectral 
count of each protein was then converted into a Normalized Spectral Count (NSpC), 
expressed as the spectral count in relation to its molecular weight and relative protein amount 
in percentage, using the following equation(Zybailov et al. , 2006): 
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where NpSpCk is the percentage of the normalised spectral count for protein k, SpC is the 
spectral count, and Mw is the molecular weight in KDa for protein k. 
3. Results and Discussion 
3.1 Characterization of MBs dispersions by flow cytometry 
In this study we have tested two distinct types of MBs, those with a polymer shell of 
poly(vinyl alcohol) (PVA) and MBs prepared via a layer by layer (LBL) approach (Brismar, 
Grishenkov, 2012, Cavalieri et al. , 2005, He et al. , 2012, Peyratout and Dahne, 2004). While 
for the first set of particles, the PVA polymer stabilized the MBs against aggregation (similar 
to PEG modification), (Cerroni et al. , 2011, de Gennes, 1987) LBL MBs have been modified 
by layer by layer deposition of polymers on the MBs core. LBL MBs exhibit either a 
positively or negatively charged surface depending on the peripheral exposed layer and they 
are electrostatically stabilized due to the repulsion between charged particles. In this study we 
have tested 10 types of MBs (Table 1), here we discuss the results mainly from 6 examples of 
MBs: PVA, PVA shelled MBs decorated with iron oxide nanoparticles (Type B), and four 
types of LBL coated MBs (specifically LBL02, LBL03, LBL04 and LBL08). 
MB concentration and size distribution are traditionally determined by confocal laser 
scanning microscopy, due to their “large” size, which is well above the limits of optical 
resolution, however this process is laborious and time consuming, as well as low-throughput, 
making it far from optimal for routine characterization and can potentially lead to statistically 
unreliable results. Flow cytometry is a routine method for the counting of single objects 
forced through a flow cell where they are excited by a laser. Forward scattering (FSC) and 
side scattering (SSC) are measured by detectors that are placed in line and perpendicular to 
the light source, respectively. While FSC values are directly correlated to the size of a 
scattering object, the SSC reflects the object complexity, structure and density.  Here we have 
applied flow cytometry to the characterisation of MBs for the first time, allowing larger 
numbers of MBs to be analysed with greater accuracy and with significantly higher 
throughput. 
By plotting the forward scattering values against the number of scattering objects (Figures 1-
4 panel a), it is clear that the MB population consists of sub-populations of particles with low, 
medium and high FSC intensity, suggesting the presence of both single MBs along with 
agglomerates. Plotting the SSC against the FSC, it is possible to see that the SSC of these 
sub-populations is similar (Figures 1-4b). Phase contrast microscopy of the various MB 
dispersions post-synthesis is shown in Figures 1-4c and confirms the co-existence of clusters 
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of MBs along with single MBs (Figures 1c and 4c). This is particularly enhanced for LBL08 
where large aggregates and MB clusters are detected along with single MBs (Figure 3c), 
while Type B, LBL03 and PVA samples contain mainly single MBs with only limited small 
clusters (Figures 1c, 2c and 4c). 
Taking advantage of the large size of the MBs which allows detection by flow cytometry, we 
have also used the same method to sort MB sub-populations with “high” and “medium” 
forward scattering values have been sorted and separated into different fractions by means of 
fluorescence-assisted cell sorting (FACS), allowing further characterisation, purification and 
imaging by phase contrast light microscopy. Phase contrast analysis of the sorted fractions 
has revealed that the “medium” population contained single (dispersed) MBs (Figures 1-4 e-
f) of size ca.~3 µm, while the population with high forward scattering values (ca.~105, called 
“high”) contained clusters of MBs or large aggregates as expected (Figures 1-4 d). 
A similar strong correlation between the measured FSC values (Figures 1-4 a-b) and the MBs 
dispersion stated observed by imaging (Figures 1-4 c-f) was confirmed for all the MB 
samples studied. For example, flow cytometry FSC values have indicated that LBL08 MBs 
contained a population of large MB aggregates (Figure 3a-b), and this was also confirmed by 
image analysis (Figure 3c). This can be explained by the outmost chitosan layer having a pKa 
value of 6.3 (Wang et al. , 2006). Hence, with increasing pH in physiological buffers the 
charges and the electrostatic stabilization are neutralized, resulting in aggregation of this 
particular MB sample. 
In order to correlate the forward scattering values with the MB size, calibration beads with 
known sizes (2 µm, 6 µm and 10 µm) have been characterized by flow cytometer. As shown 
in Figure S1, a good correlation between the FSC values of the MBs and the size of the 
calibration beads was observed, and indeed the measured FSC values for the MBs 
corresponded to sizes between 2 and 6 m.  
Overall these findings show that the flow cytometry forward scattering values can be used as 
a parameter to evaluate the size distribution of MBs in high throughput manner, where 
distributions of ~15,000 MBs can be characterized within a few seconds, giving full 
description and quantification of the proportion of the monodisperse versus agglomerated 
MB sub-populations in the sample.  
The same approach was then applied to study the MBs in complex biological fluids (e.g., 
human plasma). Two different concentrations of human plasma were used in order to 
determine the behaviour of the MBs under in vitro (6% v/v plasma proteins, roughly 
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corresponding to 4 mg/ml proteins) and in vivo (full plasma proteins) conditions. Figure 5 
shows the FSC and SSC for PVA MBs and a gate (labelled as P16) around the MB 
population. Human plasma (with no MBs) and MBs in PBS were also run as controls to set a 
threshold to exclude the protein background. By plotting the FSC and SSC versus the number 
of MBs, we found that the dispersion properties (size and size distribution) of the different 
MBs were not altered by transfer from PBS into human plasma since the populations 
overlapped completely. This indicates that no destabilisation of the MBs dispersions occurs 
as a result of dilution in biological fluids. When human plasma concentration was increased 
from 6% to 100%, the MBs showed identical distributions, indicating that their dispersion 
was not affected by the amount of human plasma and that the MBs retained good stability 
also in these conditions (Figure 5).  
Physico-chemical characterization of PVA stabilised MBs after incubation in full human 
blood (with cells included) has also been performed in order to characterise the MBs after 
incubation in full blood with cells, and determine eventual binding-aggregation with the cells. 
As shown in Figure 6a-b, gates were set to allow to detect and count PVA stabilised MBs 
(P16), and when human blood alone was analysed by flow cytometry no objects with similar 
SSC and FSC were detected in the gated area of the MBs (Figure 6 c-d).  However, when the 
MBs were exposed to human blood no MBs were detected in the same region (Figure 6e-f). 
Most probably, due to the similar size of MBs and red blood cells (erythrocytes), and large 
excess of erythrocytes compared to the number of MBs in full blood. As erythrocytes in 
blood are in the range 4.9-5.5 ×109 per mL and the MBs added were 106 per mL, MB 
population corresponded only to 0.02% of the total number of objects in full blood, making 
the detection really challenging in flow cytometry. Thus, in order to better visualize and 
characterize the MBs in whole blood, after 1 h incubation, samples were centrifuged to pellet 
the blood cells while the supernatant, containing buoyant MBs, was run and characterized by 
flow cytometry. We found that the signal from the red blood cells was greatly decreased by 
the centrifugation step, due to free blood cell removal and only a small amount of blood 
debris was detected in the gate of the MBs (Figure 6 g-h). In this way, a much clearer signal 
could be observed from the MB population, as shown in the FSC and SSC plots (Figure 6 g-
h). Furthermore we found that the distribution of the MBs in human blood overlapped with 
those dispersed in phosphate buffered saline (PBS) (Figure 7). This result confirmed that the 
particle size and distribution of the MBs were not significantly affected by the dispersion 
medium (PBS or human blood). The same approach can be applied to any large 
microparticles dispersed in any biological fluid.  
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3.2 Identification of proteins from coronas of microbubbles 
To fully assess the biocompatibility of MBs, we have finally investigated the hard protein 
corona formation after incubation with 10% bovine serum and 6% human plasma (note that 
the total amount of proteins in these 2 samples is equal, with only the complement proteins 
being removed in the serum), in order to mimic typical in vitro conditions (i.e., exposure 
conditions used in cell studies). In addition, MBs were also incubated with full plasma 
(100%) to simulate the environment of the blood stream. As discussed above, current 
protocols to isolate particles with their protein coronas are not easily applied to MBs, as they 
rely on particle sedimentation under centrifugal force, whereas MBs are buoyant and thus do 
not sediment (Cedervall, Lynch, 2007, Monopoli, Walczyk, 2011). By taking advantage of 
MBs buoyancy, MBs were incubated with plasma and subsequently MB-hard protein corona 
complexes were isolated as described in Materials and Methods. 
Interestingly, strong similarities were observed for all the different types of MBs in the 
protein coronas recovered after incubation in 6% and in full human plasma. As shown in 
Figure 8, a predominant protein band at 70 kDa, later identified as serum albumin, was 
consistently found in all cases. Other protein bands at 150, 80, 60, 50 and 25 kDa were also 
observed, with similar patterns across all the different MB samples assessed. No dramatic 
differences in protein band patterns were found in the coronas of the differently surface-
functionalized MBs. A similar pattern was also obtained for several different kinds of MBs 
studied when coronas were formed in serum, rather than plasma, suggesting that the different 
surface properties of the MBs do not lead to a significant difference in the protein corona 
composition, likely due to the loss of surface curvature effects present for nanoscale particles.  
Mass spectrometry (MS) was then used in order to identify the different classes of proteins in 
the MBs-protein coronas. The most abundant proteins identified by MS are given in Tables 2 
and 3. The MS analysis confirmed that serum albumin was overall the most abundant protein 
in the MB-protein coronas after incubation with 6% plasma, 10% serum and full plasma. In 
fact, we observed that serum albumin accounts for between 8 - 55% of the total protein 
content in the MB coronas. The percentage varied depending on the nature of the biological 
fluid and the type of MBs (PVA, Type B, LBL02 and LBL04). For example, in 10% serum, 
the serum albumin in the MBs coronas made up over 50% of the total protein corona content 
for all four types of MBs. Alpha 2 glycoprotein, serotransferrin and Apolipoprotein A1, 
which are carrier proteins in the bloodstream to mediate the transport of ions, iron and lipids 
respectively, were also highly abundant within the MB protein coronas. These three proteins’ 
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NSpC values varied in the range 16.9% - 18.5%, 5.7% - 7% and 3.1% - 8.2% respectively 
(Table 2). Alpha-1antiproteinase, a coagulation protein inhibitor, made up approximately 5% 
of the MB protein coronas. The rest of the most abundant proteins accounted for 
approximately 1% of the NSpC.  
In 6% plasma, serum albumin was also the most abundant protein. The NSpC values of 
albumin for PVA, Type B, LBL02 and LBL04 MBs were between 31.6 and 46%. Several 
other carrier proteins were also significantly abundant, including serotransferrin and 
apolipoprotein B100. Immunoglobulin light chain kappa proteins were also detected among 
the corona proteins for all four MBs, with abundance between 6 and 15%. Complement C3 
protein, a key protein of the complement protein cascade involved in blood coagulation, was 
associated with the MBs but in lower quantities.  
Serum albumin, transferrin and apolipoprotein A1 are known as disopsonin proteins, which 
function to suppress phagocytosis (clearance by macrophages). In contrast, their counterpart, 
opsonin proteins, such as immunoglobulin and complement proteins which promote 
phagocytosis, were not particularly enriched in the MBs coronas (Ishida, Harashima, 2001, 
Owens and Peppas, 2006). Additionally, the ratio between disopsonin and opsonin proteins 
was high. This may suggest that the MBs in 6% plasma and 10% serum are not likely to 
trigger phagocytic pathways via their protein corona (for example, for in vitro cell studies), 
indicating a high biocompatibility of the MBs. Similarly, in full plasma, the MBs had a 
similar corona composition as in 6% plasma and 10% serum. However, the serum albumin 
showed the lowest abundance (8.1~17.1%) in full plasma, compared to 31.6 - 46% and 50.6 - 
52.9% in 6% plasma and 10% serum respectively. This suggested that protein binding to 
MBs was significantly affected by the total protein concentrations, and that in vitro studies 
may not be entirely predictive of in vivo behaviour. Several disopsonin proteins (e.g., serum 
albumin, serotransferrin and lipoproteins) were among the major components of the protein 
corona formed on all types of MBs (PVA, Type B, LBL02, and LBL04) also in full plasma, 
however several opsonin biomolecules  were found as corona binding proteins when exposed 
to full plasma. In particular Immunoglobulin G and complement C3 were detected in the 
corona suggesting that they might promote recognition by macrophages, resulting in the 
potential to induce an immune response and opsonisation (Hamad et al. , 2010). However, the 
presence of these biomolecules in the corona does not directly imply biocompatibility 
concerns as immunogenic epitopes of these proteins, such as the constant regions of the 
antibody, as they can be buried in the biomolecular corona and they might not be available 
for binding. (Kelly et al. , 2015). Overall the protein corona proteomics suggest high 
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biocompability of the MB in vitro and in vivo conditions however further studies will map 
the binding sites of the corona in order to fully evaluate their impact in biological 
environment.  
 
 
4. Conclusions 
We have developed and demonstrated the use of flow cytometry as a new technique to 
characterize the dispersions of polymer coated MBs in complex biological fluids such as 
human plasma and full blood where this method allows to overcome the experimental 
challenges associated with working with such buoyant materials. Flow cytometry sorting has 
also been used as an efficient novel tool to separate monodisperse MBs from multi-
population dispersions (e.g. cellular and/or MB debris and MB agglomerate) even where the 
single MBs constituted the minority of the sample and it can be used as a useful post–
synthesis cleaning step, increasing the quality of the contrast agent (Figure 3). By setting 
appropriate gate(s) for forward and side scattering, MBs can be isolated in less than 1h per 
mL of blood in an automatic manner. Importantly, this approach can also be applied to 
investigate interactions of such particles with full blood, and other biological media, and 
therefore predict the likely effective interactions between MBs and cells, in situ.  
In addition, we believe that this method can be applied to recover the MBs after their in vivo 
exposure, such as in animal studies. The isolation of MBs by flow cytometry is relatively 
easy and fast compared to previously applied methods, such as phase contrast microscopy. 
While using high resolution microscopy only 10-100 MBs can be analyzed, within 20 min, 
whereas the flow cytometer can analyze more than 50,000 MBs per minute.  
Thus here, we have this method to characterise multiple types of surface functionalized, 
polymer coated MBs, developed for multimodal imaging applications as in vivo contrast 
agents. Assessment of the composition of their protein coronas following incubation under in 
vitro (6% plasma or 10% serum) and in vivo (full human plasma) conditions have been 
carried out in order to study the biocompatibility of several representative MBs. This study 
shows that there is very little difference observed in terms of the proteins bound to the 
different types of MBs, suggesting that lack of surface curvature of the MBs may play a more 
prominent role than surface functionalization in driving protein binding to the MBs. Since 
MBs are generally in the size range of 2~6 µm in diameter, they may be large enough to 
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behave as flat surfaces for binding of proteins. This is very different from protein binding to 
nanoscale objects, where even small variations in surface properties play important roles in 
protein corona composition driven or enhanced by their high surface curvature. 
Mass spectrometry results indicated the presence of several disopsonin proteins in the MB 
coronas, e.g. serum albumin, transferrin and apolipoprotein A1, which are known to suppress 
phagocytosis. A lack of opsonin proteins, such as immunoglobulin and complement proteins 
which are known to promote phagocytosis, was observed in 10% serum treated MBs. 
Additionally, it was found that since the ratio between disopsopin and opsonin proteins was 
fairly high, MBs existing in in vitro conditions may indicate higher biocompatibility of MBs 
that is actually the case in vivo.  
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Figure Captions 
Figure 1. Flow cytometry and microscopy analysis of Type B MBs dispersed in PBS. (a) 
Forward scattering distribution (FSC-A); (b) double scatter plot of side scattering versus 
forward scatering of Type B MBs obtained by flow cytometry. Different gates are applied (as 
indicated by the different colors) in order to distinguish MBs with low FSC (blue) from those 
with medium (green, sorted medium) and high (purple, sorted high) FSC. These gates have 
been applied to sort the different MB sub-populations; (c) Phase contrast image of unsorted 
Type B MBs; (d-e) Phase contrast micrographs of the seperated fractions of Type B MBs 
with high FSC (sorted high) and medium FSC (sorted medium), respectively, from (b). (f) 
Enlargement of MBs from (e). 
Figure 2. Flow cytometry and microscopy analysis of LBL03 MBs dispersed in PBS. (a) 
Forward scattering distribution (FSC-A); (b) double scatter plot of side scattering versus 
forward scatering of LBL03 MBs obtained by flow cytometry. Different gates are applied (as 
indicated by the different colors) in order to distinguish MBs with low FSC (blue) from those 
with medium (green, sorted medium) and high (purple, sorted high) FSC. These gates have 
been applied to sort the different MB sub-populations; (c) Phase contrast image of unsorted 
LBL03 MBs; (d-e) Phase contrast micrographs of the seperated fractions of LBL03 MBs with 
high FSC (sorted high) and medium FSC (sorted medium), respectively, from (b). (f) 
Enlargement of MBs from (e). 
Figure 3. Flow cytometry and microscopy analysis of LBL08 MBs dispersed in PBS. (a) 
Forward scattering distribution (FSC-A); (b) double scatter plot of side scattering versus 
forward scatering of LBL08 MBs obtained by flow cytometry. Different gates are applied (as 
indicated by the different colors) in order to distinguish MBs with low FSC (blue) from those 
with medium (green, sorted medium) and high (purple) FSC. These gates have been applied 
to sort the different MB sub-populations; (c) Phase contrast image of unsorted LBL08 MBs; 
(d-e) Phase contrast micrographs of the separated fractions of LBL08 MBs with high FSC 
(sorted high) and medium FSC (sorted medium), respectively, from (b). (f) Enlargement of 
MBs from (e). 
Figure 4. Flow cytometry and microscopy analysis of PVA MBs dispersed in PBS. (a) 
Forward scattering distribution (FSC-A); (b) double scatter plot of side scattering versus 
forward scatering of PVA MBs obtained by flow cytometry. Different gates are applied (as 
indicated by the different colors) in order to distinguish MBs with low FSC (blue) from those 
 20 
 
with medium (green, sorted medium) and high (purple, sorted high) FSC. These gates have 
been applide to sort the different MB sub-populations; (c) Phase contrast image of unsorted 
PVA MBs; (d-e) Phase contrast micrographs of the separated fractions of PVA MBs with 
high FSC (sorted high) and medium FSC (sorted medium), respectively, from (b). (f) 
Enlargement of MBs from (e). 
Figure 5. (a) Flow cytometry scatter plot of FSC and SSC of (from the left) full plasma, 
PVA-MBs dispersed in PBS, PVA-MBs in 6% plasma and PVA-MBs in full plasma. A gate, 
set as P16, was made to mark the MB population only omitting the background. (b-c) Flow 
cytometry plots of FSC and SSC relative to the number of events counted in P16 for PVA-
MBs in plasma under (b) in vitro conditions and (c) in vivo conditions (red line).  
Figure 6. PVA MB characterization by flow cytometry in full blood. (a) FSC and SSC of 
PVA MBs dispersed in PBS (b) Magnification of gated area that contains MBs. (c) FSC and 
SSC of full blood; (d) Magnification of gated area that contains MBs. (e) FSC and SSC of 
PVA MBs in full blood; (f) Magnification of gated area containing MBs. (g) FSC and SSC of 
MBs in full blood following centrifugation to reduce the background scattering from 
erythrocytes, resulting in more accurate visualization of the PVA MBs by flow cytometry . 
(b), (d), (f) and (h) are the enlargement of the MBs populations (red outlines) in the graphs 
(a), (c), (e) and (g) respectively. 
Figure 7. FSC (a) and SSC (b) distribution by flow cytometry of PVA MBs  in PBS (black 
line) and in full blood (red line).  
Figure 8. SDS-PAGE gel showing a comparison of the protein coronas associated with the 
different types of MBs after incubation with 6% plasma (a), 10% serum (b), and full plasma 
(c).  
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Table 1. Summary descriptions of the MBs used in the study in terms of their composition 
and outer surface layer charge. 
Name Inner layer outer layer Charge of the outmost layer 
PVA 
- - - 
TypeB - - - 
LBL02 AG - positive 
LBL03 AG PSS negative 
LBL04 AG PMAA negative 
LBL06 AG Albumin negative 
LBL07 AG/PSS PAH positive 
LBL08 AG/PSS Chitosan  positive 
LBL10 AG/PSS PAOEt positive 
LBL11 AG/PSS PDA positive 
PVA: poly(vinyl alcohol); Type B: superparamagnetic iron oxide nanoparticles embedded in 
PVA shell; AG: aminoguanidine; PSS: Polystyrene sulfonate; PMAA: (Poly(methacrylic 
acid), PAH: (polyallyalmine), PAOEt: (Poly(methacryloxyethyltrimethylammonium) 
bromide, PDA: (Poly(diallyldimethylammonium chloride)  
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Table 2. MS analysis of protein coronas associated with MBs (PVA, Type B, LBL02 and LBL04) under in vitro conditions (MBs incubated in 
10% serum or 6% plasma). Protein abundance is expressed as the Spectral Count (Spc) and Normalised SpC (NSPc). 
10% Serum (in vitro conditions) 
 
SpC 
   
NSpC 
  
Accession Protein indentity Mw (Da) PVA TypeB  LBL02 LBL04 PVA TypeB LBL02 LBL04 
P02769 Serum albumin 69249 155 190 188 209 52.9 52.4 50.6 52.9 
P12763 Alpha 2 glycoprotein  38394 30 34 37 39 18.5 16.9 18.0 17.8 
Q29443 Serotransferrin 77703 22 23 33 31 6.7 5.7 7.9 7.0 
P34955 Alpha-1antiproteinase 46075 10 11 13 12 5.1 4.6 5.3 4.6 
Q7SIH1 Alpha-2macroglobulin 167470 8 16 19 16 1.1 1.8 2.1 1.7 
P15497 Apolipoprotein A-I  30258 4 13 11 11 3.1 8.2 6.8 6.4 
 
6% plasma (in vitro conditions) 
 
SpC 
   
NSpC 
  
Accession Protein indentity Mw (Da) PVA TypeB LBL02 LBL04 PVA TypeB LBL02 LBL04 
P02768 Serum albumin 69322 414 319 430 279 31.6 45.8 40.8 46.6 
P01857 Ig gamma 1 chain  36083 58 26 43 24 8.5 7.2 7.8 7.7 
P01023 Alpha 2macroglobulin  163187 51 13 36 5 1.7 0.8 1.5 0.4 
P02787 Serotransferrin  77014 42 27 52 23 2.9 3.5 4.4 3.5 
P01024 Complement C3  187029 41 53 40 38 1.2 2.8 1.4 2.4 
P04114 Apolipoprotein B100  515284 39 76 52 64 0.4 1.5 0.7 1.4 
P01834 Ig kappa chain C region 11602 34 8 19 9 15.5 6.9 10.8 9.0 
P00738 Haptoglobin  45177 21 8 23 0 2.5 1.8 3.3 0.0 
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Table 3. MS analysis of protein coronas associated with MBs (PVA, Type B, LBL02 and 
LBL04) under in vivo conditions (MBs incubated in full plasma). Protein abundance is 
expressed as the Spectral Count (Spc) and Normalised SpC (NSPc). 
    Full plasma (in vivo conditions)    SpC  
Accession Protein Identity Mw (Da) PVA Type B LBL02 LBL04 
P02768 Serum albumin 69322 154 152 170 296 
P01834 Ig kappa chain C region  11602 15 8 26 56 
P02787 Serotransferrin  77014 67 45 60 138 
P01620 Ig kappa chain V-III  11768 7 3 4 13 
P01857 Ig gamma-1 chain  36083 17 10 15 40 
P01009 Alpha-1-antitrypsin  46707 21 11 20 53 
P02647 Apolipoprotein A-I  30759 13 2 22 36 
P02675 Fibrinogen beta chain  55892 22 8 17 43 
B9A064 Ig lambda-1  23049 8 12 10 23 
P01024 Complement C3 187029 60 57 88 154 
 
Full plasma (in vivo conditions) 
  NSpC   
Accession Protein Identity Mw (Da) PVA Type B LBL02 LBL 04 
P02768 Serum albumin 69322 11.4 17.1 8.1 8.4 
P01834 Ig kappa chain C  11602 6.6 5.4 7.4 9.5 
P02787 Serotransferrin  77014 4.5 4.6 2.6 3.5 
P01620 Ig kappa chain V-III  11768 3.1 2.0 1.1 2.2 
P01857 Ig gamma-1 chain  36083 2.4 2.2 1.4 2.2 
P01009 Alpha-1-antitrypsin  46707 2.3 1.8 1.4 2.2 
P02647 Apolipoprotein A-I  30759 2.2 0.5 2.4 2.3 
P02675 Fibrinogen beta chain  55892 2.0 1.1 1.0 1.5 
B9A064 Ig lambda-1 23049 1.8 4.1 1.4 2.0 
P01024 Complement C3 187029 1.6 2.4 1.6 1.6 
 
